News & Events
News & Events
September 14, 2022
C-Path Awarded FDA Grant to Establish Public-Private Partnership to Advance Treatments for Rare Neurodegenerative Diseases
C-Path has announced it will serve as the convener of the Critical Path for Rare Neurodegenerative Diseases (CP-RND), a new public-private partnership (PPP) to benefit people across multiple rare neurodegenerative diseases, supported by a grant from the U.S. Food and Drug Administration (FDA). The Agency announced the PPP today in a press release.
September 8, 2022
C-Path’s Kristen Swingle Named PresidentSwingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path...
September 1, 2022
C-Path to Lead Pre-Consortium Aimed at Transforming, Accelerating Medical Product Development in Lysosomal Diseases
C-Path today announced the launch of a pre-consortium collaboration focused on accelerating medical product development in lysosomal diseases, supported by a grant from the U.S. Food and Drug Administration (FDA).
August 25, 2022
Upcoming Rare Disease Workshop Focuses on the Importance of Data Sharing in Drug DevelopmentC-Path, NORD and FDA to host annual workshop September 13-14 to highlight the impact of their innovative data and analytics platform on rare disease drug development TUCSON, Ariz. and WASHINGTON, DC, August 25, 2022 — The Rare Disease Cures Accelerator-Data and Analytics Platform initiative (RDCA-DAP®) will host its in-person annual workshop on September 13...
September 30, 2021
C-Path and Pulse Infoframe Establish Patient-Centered Data Harmonization Partnership to Accelerate Collaborative Research in Rare Disease
Critical Path Institute (C-Path) and Pulse Infoframe announced today their collaboration to advance technologies and tools to further rare disease research and drug development. In addition, both organizations will support the creation of more streamlined and transparent informed consent processes and best practices for the development of global unique identifiers, data standards and data dictionaries.